Breaking News from ESCRS

March 13th 2025

PHOTON Results and Their Relation to DME Patients in Your Practice

SpliceBio continues to actively enroll patients in the ASTRA study and accompanying POLARIS trial

July 25th 2024

Her Royal Highness The Duchess of Edinburgh delivers keynote address on gender equity in eye care

John Kitchens, MD, is joined by Diana Do, MD, to discuss the PHOTON trial results and their relation to patients with diabetic macular oedema in clinical practice.

Left to Right – Back Row: Peter Holland, CEO, IAPB, H.E. Gladys Mokhawa, Permanent Representative of Botswana to the United Nations, H.E Ambassador Walton Webson, Permanent Representative of Antigua and Barbuda to the United Nations & Co-Chair and Founder of the UN Friends of Vision Group, Dr. A.H. Monjurul Kabir, Global Adviser and Team Leader, Gender Equality and Disability Inclusion, Mr. Werner Obermeyer, Director WHO, New York Front Row: Jennifer Gersbeck, Executive Director – Influence and Scaling Impact at The Fred Hollows Foundation and Co-Chair of the IAPB Gender Equity Work Group, HRH The Duchess of Edinburgh, Ms Tara Soomro, Permanent Mission of United Kingdom to the United Nations & Ambassador ECOSOC Affairs . Image courtesy of the International Agency for the Prevention of Blindness.

March 12th 2025

PULSAR Results and Their Relation to nAMD Patients in Your Practice

The UN Friends of Vision group meeting coincided with International Women's Day and the UN Commission on the Status of Women

July 24th 2024

OKYO Pharma files US FDA Fast Track application for neuropathic corneal pain treatment urcosimod

John Kitchens, MD, is joined by David Brown, MD, to discuss the PULSAR study results and their relation to patients with neovascular age-related macular degeneration in clinical practice.

A black-and-white image of a woman placing her hand over her eye, as if in pain. A red glow on her eye area indicates she is experiencing neuropathic corneal pain. Image credit: ©mykolasamoilenk – stock.adobe.com

Martin David Harp

Renal dysfunction negatively impacts effect of diabetic macular oedema therapy

Urcosimod, formerly known as OK-101, showed clear statistical significance in multiple endpoints in a recently completed Phase 2 trial

A close-up of an eyeball looking at the tip of a syringe needle. There is a droplet of liquid coming from the syringe. Concept image for anti-VEGF and diabetic macular oedema. Image credit: ©kikkerdirk – stock.adobe.com

Lynda Charters

First patient dosed in Phase 1/2 ASTRA study for Stargardt disease therapy SB-007 (SpliceBio)

Additionally, the prognosis of macular oedema may help clinicians evaluate renal function, investigators reported

Related Content

March 13th 2025

PHOTON Results and Their Relation to DME Patients in Your Practice

SpliceBio continues to actively enroll patients in the ASTRA study and accompanying POLARIS trial

July 25th 2024

Her Royal Highness The Duchess of Edinburgh delivers keynote address on gender equity in eye care

John Kitchens, MD, is joined by Diana Do, MD, to discuss the PHOTON trial results and their relation to patients with diabetic macular oedema in clinical practice.

March 12th 2025

PULSAR Results and Their Relation to nAMD Patients in Your Practice

The UN Friends of Vision group meeting coincided with International Women's Day and the UN Commission on the Status of Women

July 24th 2024

OKYO Pharma files US FDA Fast Track application for neuropathic corneal pain treatment urcosimod

John Kitchens, MD, is joined by David Brown, MD, to discuss the PULSAR study results and their relation to patients with neovascular age-related macular degeneration in clinical practice.

Martin David Harp

Renal dysfunction negatively impacts effect of diabetic macular oedema therapy

Urcosimod, formerly known as OK-101, showed clear statistical significance in multiple endpoints in a recently completed Phase 2 trial

Lynda Charters